T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).
Bernard Escudier,Robert J. Motzer,Brian I. Rini,Thomas Powles,David F. McDermott,Cristina Suarez,Sergio Bracarda,Walter M. Stadler,Frede Donskov,Howard Gurney,Stéphane Oudard,Motohide Uemura,Elaine T. Lam,Carsten Grüllich,Beiying Ding,Tarik Khaznadar,Caroleen Quach,Elisabeth Piault,Christina Schiff,Michael B. Atkins +19 more
TL;DR: The randomized, open-label Phase III IMmotion151 study met its coprimary endpoint in PD-L1+ patients with improvement in investigator-assessed PFS for atezo + bev vs sun with encouraging efficacy observed in the intent-to-treat (ITT) population.
Journal ArticleDOI
A comparison of the platinum analogues in bladder cancer cell lines.
TL;DR: It is suggested that oxaliplatin is a potent agent in bladder cancer cell lines and is superior to carboplatin in this in vitro setting, which justifies the clinical studies using this drug that are underway.
Proceedings ArticleDOI
Abstract CT081: Molecular correlates of differential response to Atezolizumab +/- Bevacizumab vs Sunitnib in a Phase II study in untreated metastatic renal cell carcinoma (RCC) patients
David F. McDermott,Mahrukh Huseni,Brian I. Rini,Robert J. Motzer,Michael B. Atkins,Berard Escudier,Dorothee Nickles,Zach Boyd,Shruthi Sampath,Jennifer Doss,Ning Leng,Christina Schiff,Daniel S. Chen,Gregg Fine,Thomas Powles,Priti S. Hegde +15 more
TL;DR: In this paper, a phase II trial that compared atezo+/-bev vs sunitinib (sun) in untreated metastatic renal cell carcinoma (RCC) patients, encouraging antitumor activity of bevacizumab (bev) vs sun was observed in PD-L1 expressing tumors.
Journal ArticleDOI
Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC)-an International mRCC Database Consortium (IMDC) analysis
Daniel Vilarim Araujo,Connor Wells,Aaron R. Hansen,Nazli Dizman,Sumanta K. Pal,Benoit Beuselinck,Frede Donskov,Chun Loo Gan,Flora Yan,Ben Tran,Christian Kollmannsberger,Guillermo Velasco,Takeshi Yuasa,M. Neil Reaume,D. Scott Ernst,Thomas Powles,Georg A. Bjarnason,Toni K. Choueiri,Daniel Y.C. Heng,Shaan Dudani +19 more
TL;DR: In this paper, the authors compared the efficacy of ICI treatments in older vs. younger adults with metastatic renal cell carcinoma (mRCC) registration trials using the International mRCC Database Consortium (IMDC), patients treated with a PD(L)-1 based ICI were identified.
Book ChapterDOI
HIV-related testicular cancer.
TL;DR: Two recent reports, and another large series confirm that testicular cancer is more common compared to age matched controls (relative risk 3.9), and seminoma occurs more frequently than non seminoma.